Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection

Journal of Experimental Medicine

Volumn 188, Issue 4, 1998, Pages 725-734

  Engel, Juan C ^a,c   Doyle, Patricia S ^a   Hsieh, Ivy ^a   McKerrow, James H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Tropical Disease Research Unit   (United States)

Author keywords

Chagas' disease; Cysteine protease; Drug design; Protease inhibitors; Trypanosoma cruzi

Indexed keywords

CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; KETONE; PHENYLALANINE; PIPERAZINE; PSEUDOPEPTIDE; SULFONE DERIVATIVE; UREA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD CULTURE; CHAGAS DISEASE; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GOLGI COMPLEX; IMMUNOCYTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; CHAGAS DISEASE; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; MACROPHAGES; MICE; MICE, INBRED C3H; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 0032541311     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.4.725     Document Type: Article

References (36)

1. Libow, L.F., V.P. Beltranni, D.N. Silvers, and M.E. Grossman. 1991. Post-cardiac transplant reactivation of Chagas' disease diagnosed by skin biopsy. Cutis. 48:37-10.
2. Godal, T., and J. Nagera. 1990. Tropical diseases. In WHO Division of Control in Tropical Diseases, 12-13. World Health Organization; Geneva, Switzerland.
3. The National Foundation of Brazil. 1996. Etiological treatment for Chagas' disease. Parasitol. Today. 13:127-128.
4. Parada, H., H.A. Carrasco, N. Anez, and I. Inglessis. 1997. Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study. Int. J. Cardiology. 60:49-54.
5. Chagas, C. 1981. Carlos Chagas: Coletanea de trabalhos cientificos. Editora Universidade de Brasilia. 6:247-258.
6. Di Lorenzo, G.A., M.A. Pagano, A.L. Taratuto, M.L. Garau, F.J. Meli, and M.D. Pomsztein. 1996. Chagasic granulomatous encephalitis in immunosuppressed patients. Computed tomography and magnetic resonance imaging findings. J. Neuroimaging. 6:94-97.
7. Pimentel, P.C., B.W. Handfas, and M. Carmignani. 1996. Trypanosoma cruzi meningoencephalitis in AIDS mimicking cerebral metastasis: case report. Arq. Neuro-Psiquiatr. 54:102-106.
8. Filardi, L.S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans. Royal Soc. Trop. Med. Hyg. 81: 755-759.
9. Gorla, N.B., O.S. Ledesma, G.P. Barbieri, and I.B. Larripa. 1988. Assessment of cytogenetic damage in chagasic children treated with benznidazole. Mutat. Res. 206:217-220.
10. Kirchhoff, L.V. 1993. American Trypanosomiasis (Chagas' disease) - a tropical disease now in the United States. New Engl. J. Med. 329:639-644.
11. Cerisola, J.A., M. Alvarez, and A.M. De Rissio. 1970. Immunodiagnostico da doenca de Chagas. Evolucao serologica de pacientes com doenca de Chagas. Rev. Inst. Med. Trop. Sao Paulo. 18:357-364.
12. Andrade, S.G., J.B. Magalhaes, and A.L. Pontes. 1985. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull. W H O. 63:721-726.
13. Cazzulo, J.J., V. Stoka, and V. Turk. 1997. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol. Chem. 378:1-10.
14. Eakin, A.E., M.E. McGrath, J.H. McKerrow, R.J. Fletterick, and C.S. Craik. 1993. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. J. Biol. Chem. 9:6115-6118.
15. Ring, C.S., E. Sun, J.H. McKerrow, G.K. Lee, P.J. Rosenthal, I.D. Kuntz, and F.E. Cohen. 1993. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. USA. 90: 3583-3587.
16. Eakin, A.E., J.H. McKerrow, and C.S. Craik. 1995. A cysteine protease is a target for the enzyme structure-based design of antiparasitic drugs. Drug Inf. J. 92:1501S-1517S.
17. McGrath, M.E., A.E. Eakin, J.C. Engel, J.H. McKerrow, C.S. Craik, and R.J. Fletterick. 1995. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J. Mol. Biol. 247:251-259.
18. Ashall, F., H. Angliker, and E. Shaw. 1990. Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem. Biophys. Res. Commun. 170:923-929.
19. Meirelles, M.N., L. Juliano, E. Carmona, S.G. Silva, E.M. Costa, A.C.M. Murta, and J. Scharfstein. 1992. Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro. Mol. Biochem. Parasitol. 52:175-184.
20. Harth, G., N. Andrews, A.A. Mills, J.C. Engel, R. Smith. and J.H. McKerrow. 1993. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol. Biochem. Parasitol. 58:17-24.
21. Engel, J.C., P.S. Doyle, J. Palmer, I. Hsieh, D.F. Bainton, and J.H. McKerrow. 1998. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci. 111:597-606.
22. Stenberg, P.E., M.A. Schuman, S.P. Levine, and D.F. Bainton. 1984. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J. Biol. Chem. 98:748-760.
23. Kjeldsen, L., D.F. Bainton, H. Sengelov, and N. Borregaard. 1993. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation. Blood. 82:3183-3191.
24. Laemli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 222:680-685.
25. Zhang, D. 1998. The roles of cytochrome P450 3A and P-glycoprotein in the absorption, metabolism and elimination of a novel cysteine protease inhibitor. Ph.D. thesis. University of California, San Francisco.
26. Tarleton, R.L., L. Zhang, and M.O. Downs. 1997. Autoimmune rejection of neonatal heart transplants in experimental Chaga's disease is a parasite-specific response to infected host-tissue. Proc. Natl. Acad. Sci. USA. 94:3932-3937.
27. Viotti, R., C. Vigliano, H. Armenti, and E.L. Segura. 1994. Treatment of chronic Chagas' disease with benznidazole: clinical and serological evolution of patients with long-term follow up. Am. Heart J. 127:151-162.
28. Andrade, S.G., S. Stocker-Guerret, A.S. Pimentel, and J.A. Grimaud. 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem. Inst. Oswaldo Cruz 86:187-200.
29. Robertson, C.D., G.H. Coombs, M.J. North, and J.C. Mottram. 1996. Parasite cysteine proteinases. Perspect. Drug Discov. Des. 6:1-20.
30. McKerrow, J.H., M.E. McGrath, and J.C. Engel. 1995. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol. Today 11:279-282.
31. Eichhold, T.H., E.B. Hookfin, Y.O. Taiwo, B. De, and K.R. Wehmeyer. 1997. Isolation and quantification of fluoroacetate in rat tissues following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor. J. Pharm. Biochem. Anal. 16:459-467.
32. Marinkelle, C.J., and E. Rodriguez. 1968. The influence of environmental temperature on the pathogenicity of Trypanosoma cruzi in mice. Exp. Parasitol. 23:260-263.
33. Bertelli, M.S., R.R. Golgher, and Z. Brener. 1977. Intraspecific variation in Trypanosoma cruzi: effect of temperature on the intracellular differentiation in tissue culture. J. Parasitol. 63:434-437.
34. Fresno, M., C. Hernandez-Munain, J. de Diego, L. Rivas; J. Scharfstein, and P. Bonay. 1994. Trypanosoma cruzi identification of a membrane cysteine proteinase linked through a GPI anchor. Braz. J. Med. Biol. Res. 27:431-137.
35. Nascimento, A.E., and W. de Souza. 1996. High resolution localization of cruzipain and Ssp4 in Trypasonoma cruzi by replica staining label fracture. Biol. Cell. 86:53-58.
36. McKerrow, J.H., and M.N.G. James. 1996. Cysteine proteases: evolution, function, and inhibitor design. Perspect. Drug Discov. Des. 6:1-125.